News & Updates

Patients with severe alopecia areata (patchy baldness) had a dramatic hair regrowth, without serious adverse events, when treated with an investigational Janus kinase (JAK) inhibitor in the phase III THRIVE-AA2 study presented at AAD 2023.

Treatment with the oral highly selective JAK1 inhibitor ivarmacitinib appears to help reduce disease activity in patients with moderate-to-severe atopic dermatitis (AD), with up to 42 percent of them having complete or near-complete clearance of involved skin areas, according to the results of the pivotal phase III QUARTZ3 trial presented at AAD 2023.

Subclinical, obstructive coronary atherosclerosis contributes to a more than eightfold increase in the risk for myocardial infarction among asymptomatic individuals, a study has shown.

A free online telepharmacy service, developed in the Philippines during the COVID-19 pandemic, may be used to provide and simplify medication information as part of primary care, reports a study.